# Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya

> **NCT02325440** · PHASE4 · UNKNOWN · sponsor: **University Hospital Muenster** · enrollment: 15 (estimated)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Fingolimod
- **DRUG:** Natalizumab

## Key facts

- **NCT ID:** NCT02325440
- **Lead sponsor:** University Hospital Muenster
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-03
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2014-12-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02325440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02325440, "Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02325440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*